Onderneming Dova Pharmaceuticals, Inc.
Aandelen
DOVA
US25985T1025
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- USD | -.--% | -0,07% | +269,92% |
2019 | Transcript : Dova Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019 | |
2019 | Transcript : Dova Pharmaceuticals, Inc. - Special Call |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mahmood Ladha
PSD | President | 60 | 12-11-19 |
Lee F. Allen
CTO | Chief Tech/Sci/R&D Officer | 72 | 01-04-17 |
Marc Banjak
LAW | General Counsel | - | - |
Bill L. Nichols
SAM | Sales & Marketing | - | 15-02-18 |
Stephen Crane
SAM | Sales & Marketing | - | - |
Caroline Diaz
LAW | General Counsel | - | - |
Corporate Secretary | 49 | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Henrik Stenqvist
BRD | Director/Board Member | 57 | 12-11-19 |
Guido Oelkers
BRD | Director/Board Member | 59 | 12-11-19 |
Director/Board Member | 55 | 12-11-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 28 821 405 | 13 851 527 ( 48,06 %) | 0 | 48,06 % |
Bedrijfsgegevens
Dova Pharmaceuticals, Inc.
240 Leigh Farm Road Suite 245
27707, Durham
+919-748-5975
http://www.dova.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+269,92% | 808 mln. | |
+15,89% | 121 mld. | |
+19,74% | 113 mld. | |
+17,47% | 26,02 mld. | |
-24,99% | 19,39 mld. | |
-19,51% | 15,91 mld. | |
-18,40% | 15,09 mld. | |
-46,87% | 15,06 mld. | |
+62,76% | 14,93 mld. | |
+5,49% | 13,85 mld. |
- Beurs
- Aandelen
- Koers DOVA
- Onderneming Dova Pharmaceuticals, Inc.